Common equity is likely worthless in the Chapter 11 process; the stalking horse bid from Teva sets a floor for asset value but equity holders are junior to secured debt and DIP financing. The PDUFA date of November 14, 2026 could increase competitive bidding for the assets if the sNDA is approved, but equity recovery remains highly unlikely. Monitor the 363 auction for any higher bids that could increase creditor recoveries.
Price Chart
Executive Summary
BioXcel Therapeutics announced it has entered into a stalking horse asset sale agreement with Teva Pharmaceuticals for substantially all assets, including IGALMI, and filed for Chapter 11 bankruptcy to facilitate a court-supervised sale. The company secured $19M in DIP financing from existing lenders to fund operations during the process. This filing confirms the distressed outcome signaled by the prior week's credit amendment, with the PDUFA date of November 14, 2026 now a key catalyst for the sale process.
Key Facts
- BioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals International GmbH for substantially all assets, including IGALMI and the pending sNDA for BXCL501.
- The company and its subsidiaries have commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware.
- Teva will serve as the sole 'stalking horse bidder' in a court-supervised 363 auction process.
- The company secured a commitment for $19 million in debtor-in-possession (DIP) financing from its existing secured lenders to support ongoing operations.
- The FDA has assigned a PDUFA target action date of November 14, 2026 for the BXCL501 sNDA for at-home use.
Financial Impact
Company filing for Chapter 11 bankruptcy with $19M DIP financing commitment; asset sale to Teva as stalking horse bidder; common stock likely to be delisted and equity holders likely receive no recovery.
Risk Factors
- Equity holders are expected to receive no recovery in Chapter 11 given secured debt and DIP financing priority.
- The 363 auction may fail to attract higher bids, leaving Teva's stalking horse bid as the sole offer.
- Nasdaq delisting is anticipated, eliminating any residual trading value in the common stock.
- The PDUFA date of November 14, 2026 introduces binary regulatory risk that could affect asset sale value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352588 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $0.1370 | awaiting T+60 | — | — |
Aug 28, 2026 8w ago | Press Release | $0.1814 | awaiting T+60 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.7422 | awaiting T+60 | — | — |
Aug 11, 2026 10w ago | 8-K | $0.9320 | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $0.8480 | awaiting T+60 | — | — |
Jul 6, 2026 16w ago | 8-K | $1.10 | awaiting T+60 | — | — |
May 22, 2026 22w ago | Insider Cluster | $1.22 $0.8274 | ▲ +32.18% | ▲ +34.91% | — |
May 20, 2026 22w ago | 144 | $1.14 $0.8900 | ▼ −21.93% | ▼ −26.23% | — |
May 15, 2026 23w ago | 8-K | $1.14 $0.9319 | ▼ −18.25% | ▼ −22.77% | — |
May 15, 2026 23w ago | Press Release | $1.14 $0.9319 | ▲ +18.25% | ▲ +22.77% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers